Identifying people with acute lymphoblastic leukemia who are most suitable for treatment with inotuzumab ozogamicin: a plain language summary

<b>What is this summary about?</b> <b>Inotuzumab ozogamicin</b> (inotuzumab or InO for short) is a more effective treatment than standard chemotherapy for patients with <b>acute lymphoblastic leukemia</b> (<b>ALL</b> for short). InO is a particularly important therapy for ALL because it can be effective for patients in whom ALL has returned (<b>relapsed</b>) or who did not respond to a previous treatment (<b>refractory</b>). Certain patients seem to experience a greater benefit from InO than others, and there are many patient- and ALL-related factors to consider when deciding which patients should be treated with InO. <b>What were the main conclusions reported by the researchers?</b> Researchers and experts were able to identify patients with R/R ALL who would benefit the most from treatment with InO. These results may help physicians choose treatments for people with ALL. This improved understanding of the relationship between individual patients and the effectiveness of InO could help people who have ALL that is difficult to treat.